Waldencast Expands U.S. Market Presence with Novaestiq Acquisition

Waldencast ( (WALD) ) has provided an announcement.

On July 22, 2025, Waldencast plc acquired Novaestiq Corp., gaining exclusive U.S. rights to commercialize Saypha® dermal fillers, pending FDA approval. This strategic acquisition aligns with Waldencast’s expansion into the high-growth injectable dermal filler market. Following FDA approval of Saypha® MagIQ™ on September 10, 2025, Waldencast issued 3,273,000 class A shares as part of the acquisition agreement. Additionally, Waldencast amended its TCW Credit Agreement, increasing financial flexibility to support its growth initiatives.

The most recent analyst rating on (WALD) stock is a Hold with a $3.50 price target. To see the full list of analyst forecasts on Waldencast stock, see the WALD Stock Forecast page.

Spark’s Take on WALD Stock

According to Spark, TipRanks’ AI Analyst, WALD is a Neutral.

Waldencast Acquisition’s overall stock score reflects strong technical momentum and a positive outlook from recent earnings calls. However, financial performance is hindered by ongoing profitability challenges and cash flow issues, while valuation metrics remain unattractive due to negative earnings.

To see Spark’s full report on WALD stock, click here.

More about Waldencast

Waldencast plc is a global multi-brand beauty and wellness platform, aiming to build a best-in-class portfolio by acquiring and accelerating high-growth, purpose-driven brands. The company operates through two main segments: Obagi Medical, which offers advanced skincare products, and Milk Makeup, known for its vegan, cruelty-free cosmetics. Waldencast’s strategy includes expanding into the injectable dermal filler market with exclusive rights to the Saypha® line in the U.S.

Average Trading Volume: 127,939

Technical Sentiment Signal: Sell

Current Market Cap: $378M

For an in-depth examination of WALD stock, go to TipRanks’ Overview page.